PSTV
Plus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.87
−3.25%Jul 21, 2026, 11:30 UTC
Plus Therapeutics subsidiary CNSide Diagnostics signed a regional coverage agreement with Medical Mutual to provide the CNSide CSF TCE assay to approximately 1.2 million people in Ohio and Kentucky.
Source:Jun 25, 2026, 11:30 UTC
CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national coverage agreement with Elevance Health to provide the CNSide CSF TCE assay to approximately 45.4 million people in the United States.
Jun 4, 2026, 11:30 UTC
Plus Therapeutics' subsidiary CNSide Diagnostics received CAP accreditation for its Houston clinical laboratory.
Source: